

A series of
debates
to take **psoriasis**
management forward

17.00–19.00
Tuesday 9 June 2015
East Ballroom ABC
Vancouver Convention Center
Vancouver, Canada

Program

17.00–17.05 **Welcome and introduction**
Richard Langley
Dalhousie University, Halifax, Nova Scotia, Canada

17.05–17.35 **Debate 1: Is PASI 90 the new PASI 75?**
Diamant Thaçi
Comprehensive Center for Inflammation Medicine, University of Luebeck, Luebeck, Germany

Robert Bissonnette
Innovaderm Research Inc., Montreal, Québec, Canada

17.35–18.05 **Debate 2: Anti-TNFs as the gold standard for treating psoriatic arthritis: for how much longer?**

Richard Warren
University of Manchester, Manchester, UK

Wolf-Henning Boehncke
University of Geneva, Geneva, Switzerland

18.05–18.35 **Debate 3: Is it time for biologics as first-line treatment in psoriasis?**

Diamant Thaçi
Comprehensive Center for Inflammation Medicine, University of Luebeck, Luebeck, Germany

Richard Warren
University of Manchester, Manchester, UK

18.35–18.55 **Question and answer session**

Moderator: Richard Langley
Dalhousie University, Halifax, Nova Scotia, Canada

18.55–19.00 **Meeting close**

Richard Langley
Dalhousie University, Halifax, Nova Scotia, Canada

IL-17A

Supported by



Novartis Pharma AG
CH-4056 Basel, Switzerland

Invitation is extended to Healthcare Professionals only

April 2015/GMCC code GLDEIM/AIN457A/0062a/Expiry April 2016
Copyright © 2015 Novartis Pharma AG

